{"filing":{"accession_number":"0001140361-26-040332","cik":"0001635088","ticker":"ROIV","company_name":"Roivant Sciences Ltd.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"ef20084121_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126040332/ef20084121_8k.htm"},"events":[{"id":36585,"run_id":33732,"accession_number":"0001140361-26-040332","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Roivant announced positive Phase 3 trial results for brepocitinib in non-infectious uveitis (NIU), with the drug meeting primary and secondary endpoints and plans to file a supplemental NDA in H1 2027. This is a material clinical milestone for a late-stage product candidate that could support regulatory approval and commercial expansion, but it does not fit the specific event types of earnings release, M\u0026A activity, or other defined categories. The disclosure is clearly operational/strategic in nature—a significant product development milestone—making operational_other the most appropriate classification.","company_name":"Roivant Sciences Ltd.","ticker":"ROIV","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41047,"accession_number":"0001140361-26-040332","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Roivant announced positive Phase 3 trial results for brepocitinib in non-infectious uveitis (NIU), with the drug meeting primary and secondary endpoints and plans to file a supplemental NDA in H1 2027. This is a material clinical milestone for a late-stage product candidate that could support regulatory approval and commercial expansion, but it does not fit the specific event types of earnings release, M\u0026A activity, or other defined categories. The disclosure is clearly operational/strategic in nature—a significant product development milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T11:06:37.943606+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41047,"accession_number":"0001140361-26-040332","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Roivant announced positive Phase 3 trial results for brepocitinib in non-infectious uveitis (NIU), with the drug meeting primary and secondary endpoints and plans to file a supplemental NDA in H1 2027. This is a material clinical milestone for a late-stage product candidate that could support regulatory approval and commercial expansion, but it does not fit the specific event types of earnings release, M\u0026A activity, or other defined categories. The disclosure is clearly operational/strategic in nature—a significant product development milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T11:06:37.943606+00:00","company_name":"Roivant Sciences Ltd.","ticker":"ROIV","filing_date":"2026-10-21"}]}